Samsung Bioepis Co., Ltd.
http://www.samsungbioepis.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Samsung Bioepis Co., Ltd.
Sandoz Partner Samsung Bioepis Settles On Stelara In US
Samsung Bioepis has struck a US settlement with Johnson & Johnson that will allow partner Sandoz to launch the pair’s SB17 ustekinumab biosimilar to Stelara in early 2025, assuming FDA approval.
Medicare Part D Coverage For Humira Biosimilars Has Inspector General’s Attention
Office of Inspector General analysis could add momentum to reforms of the rebating system.
Samsung Bioepis Discusses Interchangeability And Adalimumab
As Samsung Bioepis seeks a US interchangeability designation for its Organon-partnered Hadlima adalimumab biosimilar, the firm’s regulatory affairs chief Byoungin Jung talks to Generics Bulletin about the significance of interchangeability for US biosimilars – and the firm’s support for legislative efforts to have all US approved biosimilars automatically designated as interchangeable.
Medicare Part D Coverage For Humira Biosimilars Has Inspector General’s Attention
Office of Inspector General analysis could add momentum to reforms of the rebating system.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Samsung Biologics
- Samsung Bioepis JV
- Samsung Bioepis BR Pharmaceutical LTDA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice